Of particular relevance to PD pathology and loss of dopaminergic neurons, the investigators also found that intraperitoneal clenbuterol treatment for 24 h reduced expression of SNCA in the substantia nigra of C57BL/6J wild-type mice, with decreases in nigral mRNA and α-syn protein. Here, SNCA is linked to Parkinson disease.